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Background: Neurologic deficit caused by cerebral ischemia defines the outcome of carotid endarterectomy (CEA).
Although few patients have clinically evident neurologic deficit, diffusion-weighted imaging (DWI) presents a number of
cases with ischemic brain lesions. This study should elucidate preoperative risk factors for perioperative microemboli that
cause brain infarction.
Methods: We studied 183 patients (58 women, 69.2 12.7 years; 125 men, 69.3  8.9 years) with high-degree carotid
artery stenosis. DWI was performed before and after CEA to analyze new cerebral ischemia. Blood samples were obtained
before operation to measure fibrinogen and C-reactive protein (CRP), and preoperative high-sensitive CRP (hsCRP) was
analyzed in 30 consecutive patients.
Results: Postoperative DWI revealed new ipsilateral ischemic lesions in 41 patients (22.4%), and eight (4.4%) showed new
neurologic deficit. Preoperative fibrinogen levels were higher in patients with new lesions (397.6 mg/dL  104.7
mg/dL) than in those without (324.7 mg/dL  74.2 mg/dL, P < .001). Preoperative levels of hsCRP were also higher
in patients with new lesions (7.9 mg/dL  5.2 mg/dL) than in those without (2.8 mg/dL  2.6 mg/dL, P  .004).
Significant association was found between fibrinogen and CRP (Spearman   0.402; P < .001) as well as hsCRP
(Spearman   0.603, P  .003). No association was found between postoperative lesions and CRP (P  .833).
Conclusion: The present study demonstrates that preoperative levels of fibrinogen and hsCRP are independent determi-
nants for new periprocedural cerebral ischemic lesions caused bymicroembolic events. There is still not sufficient evidence
to recommend measurement of CRP as a prognostic marker for perioperative cerebral lesion. (J Vasc Surg 2007;46:
449-54.)The main purpose of carotid endarterectomy (CEA) is
the prevention of stroke.1 CEA in symptomatic patients is
associated with a high incidence for the appearance of
diffusion-weighted imaging (DWI) lesions and brain in-
farction, but the cause for microembolic events remain
notional.2 Many studies have shown that raised levels of
inflammatory markers increase the risk of coronary heart
disease and the risk of ischemic or hemorrhagic stroke.3,4
Recent studies indicate a strong association between high-
sensitive C-reactive protein (hsCRP) levels and subsequent
cardiac events after interventional cardiac therapy.5 Ele-
vated fibrinogen is an important predictor of future coro-
nary events in individuals with a history of coronary heart
disease.6
The role of plasma fibrinogen as central protein in the
coagulation system has been documented by clinical evi-
dence: fibrous plaques are rich in fibrinogen and degrada-
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doi:10.1016/j.jvs.2007.05.035tion products, which are involved in mechanisms of endo-
thelial cell injury and platelet aggregation.7 It triggers the
formation of progressive atherosclerotic plaques. The rela-
tionship between high plasma fibrinogen levels, the thin
fibrous cap of atheroma, and a greater incidence of plaque
rupture and thrombosis are well known. In patients with
elevated fibrinogen levels, high numbers of inflammatory
cells are concentrated in the shoulder and cap of plaques.8
Studies on the association between several inflamma-
tory markers and postoperative cerebral lesion after CEA
are limited, however. The aim of our study was to assess
whether levels of fibrinogen, CRP, and hsCRP are useful as
predictive values of postoperative ischemic events in pa-
tients after CEA.
MATERIAL AND METHODS
Patient population. We evaluated 183 patients with
high-degree carotid artery stenosis (91 asymptomatic, 92
symptomatic patients) intended for CEA. The degree of
stenosis was evaluated by color-coded duplex ultrasound
imaging following European Carotid Surgery Trial (ECST)
criteria. All CEA were performed by experienced vascular
surgeons from January 2004 to June 2006. All patients
underwent neurologic examination 2 days before and
after the procedure.
The study was performed according to the Guidelines
of the World Medical Association Declaration of Helsinki
and was approved by the Hospital Review Board of the
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gave informed consent.
Magnetic resonance imaging (MRI) was performed
using a 1.5 Tesla whole-body imaging system (Magnetom
Symphony Quantum gradient, Siemens Medical Systems,
Erlangen, Germany) with a dedicated head coil. DWI was
performed 1 day before and after CEA. The whole brain
DWIwas done with an isotropic echo-planar sequence with
b-values of 0.500 and 1000 s/mm2, repetition time, 4006
milliseconds; echo time, 83 milliseconds; number of aver-
ages, two; slice thickness, 4 to 6 mm; 128  128 matrix
size, and 220  220 mm2 field of view. Sagittal, coronal,
and transverse views were obtained.
All MRI results were reviewed by two experienced
neuroradiologists without knowledge of vascular status and
side of operation and blinded to each other’s findings. An
acute DWI lesion (Fig 1) was only diagnosed if an increased
signal intensity was visible on two planes, if a corresponding
decreased signal intensity was detected in the apparent
diffusion coefficient image, and if both neuroradiologists
agreed on their findings.
Clinical history and physical examination were taken
with special attention to cardiovascular risk factors, as sum-
marized in Table I. Routine laboratory values, urinalysis
results, and chest radiographs were used to exclude any
inflammatory or infectious diseases. Severe cardiac disease,
coagulopathy, or any operation 6 months was an exclu-
sion criterion. Blood samples for measurement of fibrino-
gen, CRP, and hsCRP were taken from an antecubital vein
Fig 1. A postoperative diffusion-weighted image shows a lesion
(arrows) in the right parietal-cortical region.a day before operation and were immediately analyzed.Plasma fibrinogen activity was measured quantitatively
by the Clauss method, where fibrinogen is converted from
a soluble protein to an insoluble polymer by the action of
thrombin, resulting in the formation of a fibrin clot. The
thrombin clotting time is inversely proportional to the
fibrinogen concentration of the plasma. Thus, measuring
the clotting time of dilute plasma when excess thrombin is
added compared with a standardized fibrinogen prepara-
tion results in quantitative determination of fibrinogen
concentration (Dade Behring, Schwalbach, Germany).
Measurement of CRP was performed on serum using
an ultrasensitive assay based on a particle-enhanced turbi-
dimetric immunoassay technique (Dade Behring). The as-
say was performed according to manufacturer instructions.
Blood samples were mixed with the antiserum solution.
The CRP reacts specifically with latex particles coated with
antihuman CRP antibody to yield insoluble aggregates.
The increase in turbidity that accompanies aggregation is
proportional to the CRP concentration and was deter-
mined using an automated nephelometer (BNII System,
Dade Behring).
In 30 consecutive asymptomatic and symptomatic pa-
tients, we also collected blood samples before operation for
hsCRP enzyme-linked immunosorbent assay (ELISA)
analysis. The samples were centrifuged at 1600 rpm for 10
minute. The obtained serum was stored at 70°C until
laboratory testing. According to the results of Pai et al,9
who investigated the stability of plasma markers in different
time ranges, the range from sample collection until freezing
was held to a maximum of 2 hours. The hsCRP ELISA is
based on the principle of solid-hase enzyme-linked immu-
nosorbent assay (LifeDiagnostics, West Chester, Pa), with
an analytical sensitivity of0.01 mg/dL and intraassay and
interassay coefficients of variation of 4.2% and 4.1%, respec-
tively.
Statistical analysis. Data were analyzed with SPSS
13.0 (SPSS Inc, Chicago Ill). Values of continuous vari-
ables are expressed as mean  standard deviation. Groups
were compared by the Mann-Whitney Utest or matched
signed rank test. Correlations between continuous variables
were calculated using Spearman rank correlation coeffi-
cient. To investigate the relationship between binary out-
come and measured covariates, the logistic regression
model was used. Calculations of odds ratios with 95%
confidence intervals (CI) were performed and illustrated
with forest plots. Accuracy for prediction was additional
assessed by receiver operating curve (ROC) analyses;
thereby, area under the curve (AUC) and optimal cutoff
values of explanatory variables were calculated. All tests
were considered significant at P  .05.
RESULTS
Clinical characteristics of the patients are given in Table I.
Both groups were similar with regard to all analyzed risk
factors, medications, and degree of stenosis measured as
peak systolic velocity (PSV). Logistic regression analysis
showed no significant effect on the likelihood of occurring
new cerebral lesions (Fig 2).
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(14.3%) of the 91 preoperatively asymptomatic patients and
Table I. Patient characteristics
Data* Asymptomatic Symptomatic
Patients 91 (49.7) 92 (50.3)
Female 29 (31.9) 29 (31.5)
Male 62 (68.1) 63 (68.5)
Age, mean 68.8  11.1 69.7  9.4
Risk factors
Number, mean 2.2  1.1 2.2  0.9
Hypertension 81 (89.0) 82 (89.1)
Diabetes 24 (26.4) 23 (25.0)
Hypercholesterolemia 50 (54.9) 59 (64.1)
Tobacco use 40 (43.9) 41 (44.6)
Renal disease 5 (5.5) 2 (2.2)
Coronary heart disease 36 (39.6) 35 (38.0)
Medication
Thrombocyte aggregation
inhibitors 85 (93.4) 89 (96.7)
-Blocker 55 (60.4) 60 (65.2)
ACE inhibitors 48 (52.7) 43 (46.7)
Lipid-lowering agents 45 (49.5) 55 (59.8)
Degree of stenosis (PSV) 361.6  111.6 347.4  138.0
Post-op DWI lesions 13 (14.3) 28 (30.4)
New neurologic symptoms 2 (2.2) 6 (6.5)
Pre-op symptomatic patient
DWI, Diffusion-weighted image; ACE, angiotensin-converting enzyme; PS
*Categoric data are presented as numbers (%); continuous data are presente
†P obtained with 2 test.
‡P obtained with Kruskal-Wallis test.
§P obtained with Mann-Whitney U test.
P obtained with the Fisher exact test.
Fig 2. Forest plot for new cerebral ischemic lesions subject to pa-
tient characteristics, risk factors, medication, and degree of stenosis.
OR,Odds ratio;CI, confidence interval;ACE, angiotensin-converting
enzyme.28 (30.4%) of the 92 preoperatively symptomatic patientsshowed new postoperative cerebral ischemic lesions. All
lesions occurred ipsilateral to the operated side. New neu-
rologic deficits developed in eight patients, two (2.2%)
within the prior asymptomatic group and six (6.5%) within
the symptomatic group (P  .242). We saw two transient
ischemic attacks (TIAs) in the asymptomatic group, and
five TIAs and one permanent minor stroke in the symptom-
atic group.
Mean serum levels of CRP (0.79  0.71 mg/L vs
0.84  1.0 mg/L) and fibrinogen (331.2  84.5 mg/dL
vs 349.9  90.99 mg/dL) relating to asymptomatic and
symptomatic patients showed no significant difference (Ta-
ble II). Significant association was found between levels of
fibrinogen and CRP (Spearman rho 0.402; P  .001) as
well as hsCRP (Spearman rho 0.603; P .003) whereas no
association was found between postoperative lesions and
CRP (P  .833). Focusing on cerebral events, the group
with new lesions had significantly higher levels of fibrinogen
(397.6104.7mg/dL vs 324.1 75.1mg/dL, P .001)
and hsCRP (7.9  5.2 mg/dL vs 2.8  2.6 mg/dL, P 
.004). CRP (1.0  1.48 mg/L vs 0.8  0.66 mg/L, P 
.625) showed no significant difference (Figs 3, 4, and 5).
In logistic regression analysis, hsCRP (P  .048) and
fibrinogen (P  .001) showed a significant effect on the
likelihood of new cerebral lesions occurring, but CRP was
not significant (P .100). Accuracy for prediction assessed
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d as man optimal cutoff value of 4.16 (sensitivity, 0.75; specificity,
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value of 364 (sensitivity, 0.88; specificity, 0.71). The odds
ratio for a new lesion was 4.49 (95% CI, 2.12 to 9.49) by
categorized fibrinogen and 11.0 (95% CI, 1.42 to 85.2) by
hsCRP, noting that fewer measurements resulted in a large
CI for the estimated effect of hsCRP. The odds ratio
achieved by CRP with a cutoff value 0.75 was 1.75 (95%
CI, 0.81 to 3.80), thus corresponding to a weak but not
significant trend (Fig 6). The positive and negative predic-
tive value was 63.6% and 90.9% for fibrinogen and 85.7%
and 86.7% for hsCRP.
DISCUSSION
In earlier studies, we observed a significant correlation
between the number and volume of cerebral lesions inDWI
and the occurrence of brain infarction in follow-up MRI.
These findings indicate that the severity of new postopera-
tive neurologic events correlates with DWI lesion size.2
Assuming that a loss of brain tissue impairs the result of
CEA, we elucidated the influence of pre-existing activity of
atherosclerosis represented by acute-phase proteins. In-
Table II. Mean serum levels compared in asymptomatic a
Data* Asymptomatic Symptomatic
Fibrinogen (mg/dL) 331.2  84.5 349.9  90.99
CRP (mg/dL) 0.79  0.71 0.84  1.0
HsCRP (mg/dL) 3.85  3.3 5.38  5.4
*Data are presented as the mean  standard deviation.
†P obtained with Kruskal-Wallis test.
‡P obtained with Mann-Whitney U test.
Fig 3. Box plots demonstrate the mean values of fibrinogen
(mg/dL) in patients with (1) and without (0) new cerebral lesion
(P .001). The horizontal line in the middle of each box indicates
the median; the top and bottom borders of the box mark the 75th
and 25th percentiles, respectively; and the whiskers mark the 90th
and 10th percentiles.flammatory processes play a pivotal role in the pathogenesisof atheroma development to ultimate rupture of unstable
atherosclerotic plaques.5
Atherosclerosis is typically associated with low-grade
vascular inflammation that can be measured. Dosa et al5
evaluated plasma fibrinogen and serum hsCRP during
CEA. The study indicated that removal of atherosclerotic
plaques from the carotid arteries markedly decreased the
production of acute-phase proteins owing to the decrease
of inflammatory burden or the removal of the advanced
plaques able to produce these proteins.5 Increased hsCRP
levels may be related to the presence of macrophages and
T-lymphocytes in carotid plaque, which is associated with
instability that leads to ischemic events. Kondo et al10
demonstrated that plasma hsCRP is a marker of carotid
atherosclerosis activity.
Rerkasem et al11 investigated levels of inflammatory
markers between patients with symptomatic carotid steno-
sis and those who were asymptomatic. Plasma hsCRP was
elevated in symptomatic compared with asymptomatic pa-
tients. Their study showed that hsCRP was of prognostic
value in a number of cardiovascular conditions.11 In con-







.149† 320.2  74.77 397.6  104.7 .001‡
.703† 0.8  0.66 1.0  1.48 .625‡
.436† 2.8  2.62 7.9  5.24 .004‡
Fig 4. Box plots demonstrate the mean values of C-reactive pro-
tein (mg/dL) in patients with (1) and without (0) a new cerebral
lesion (P .625). The top and bottom borders of the boxmark the
75th and 25th percentiles, respectively; and the whiskers mark the
90th and 10th percentiles.nd syasymptomatic and symptomatic groups with a higher ex-
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cerebral lesions. Our results also contradict those of Choi et
a1,12 who found that a higher hsCRP level was associated
with a higher risk score of coronary heart disease but not
with carotid atherosclerosis. We also found a significant
interaction between serum levels and activity of carotid
atherosclerosis expressed in postoperative ischemic le-
sions.12
Actually, acute coronary syndromes are thought to
result from plaque rupture that is induced by the inflamma-
tory process in the atherosclerotic tissue. Patients with
non-ST elevation acute coronary syndromes who showed
no event 6 months were characterized by a decrease in
hsCRP levels from baseline to follow-up.Most events in the
observation period of 3 years occurred in patients with
follow-up hsCRP-levels 60% of the initial level. It was
Fig 5. Box plots demonstrate the mean values of high-sensitive
CRP (mg/dl) in patients with (1) and without (0) new cerebral
lesion (P  .004). The horizontal line in the middle of each box
indicates the median; the top and bottom borders of the box mark
the 75th and 25th percentiles, respectively; and the whiskers mark
the 90th and 10th percentiles.
Fig 6. Odds ratios (OR) and 95% confidence intervals (CI) for
new cerebral lesions for fibrinogen, C-reactive protein (CRP), and
high-sensitive C-reactive protein (hsCRP) in patients after carotid
endarterectomy.therefore hypothesized that a repeated measurement ofhsCRP levels in CAD patients could help to discriminate
those at high risk of further events.13 Thus determination
of circulating hsCRP levels may be a useful additional
marker of risk in patients with high-grade carotid stenosis.14
Zwaka et al15 showed hsCRP-dependent mediation of
low-density lipoprotein uptake by macrophages, and Pas-
ceri et al16 showed that hsCRP influences atherogenesis
and induces adhesion molecule expression in human endo-
thelial cells. Furthermore, Hashimoto et al17 found that
hsCRP is an independent predictor of the rate of increase of
carotid atherosclerosis.17
Tanne et al18 examined the association between CRP
levels and the subsequent risk of incident ischemic stroke
among 2979 patients with stable coronary heart disease and
showed that the risk of stroke per 1000 person-years in-
creased according to CRP levels. These findings demon-
strate the risk prediction for incident ischemic stroke
conferred by CRP levels in patients.18 Our findings contra-
dicted these results: we could not detect significant differ-
ence in CRP levels that affected postoperative cerebral
lesions.
The analysis of the EUROSTROKE project indicates
that increased fibrinogen is a powerful predictor of stroke.3
However, an increase of 100 mg/dL in a patient’s fibrino-
gen level within the range tested (between 250mg/dL and
562 mg/dL) was associated with a significantly increased
risk of heart disease and stroke. Ma et al19 found that those
with high fibrinogen levels, 343 mg/dL, had a twofold
increase in the risk of myocardial infarction (MI). A multi-
variate analysis by Coppola et al20 revealed that fibrinogen
plasma levels in patients after acuteMIwere the only indepen-
dent predictor of mortality in a 42-month follow-up after
acute MI.
Our results, together with other observations from
recent studies, suggest that fibrinogen evaluation may be
useful in identifying patients at higher risk of atherosclerosis-
associated events.20 Finally, fibrinogen may also be more
than a marker because it binds to platelets and contributes
to platelet aggregation and fibrin formation. Further stud-
ies should elucidate the connection between serum levels
and plaque morphology.
Elevated plasma levels of fibrinogen and hsCRP have
been shown to predict future risk of plaque rupture and
ischemic stroke, particularly in men and in young and
middle-aged individuals.4 Patients with high fibrinogen
levels after ischemic stroke had higher mortality rates than
patients with lower fibrinogen levels.21 Although we also
found an association between hsCRP and fibrinogen, we
could not detect any influence of sex on the laboratory
values or new postoperative DWI events. HsCRP has been
reported to reflect inflammation related to the pathology
and biology of ischemic stroke.22
Elevated levels of fibrinogen and hsCRP in patients
with carotid artery stenosis vs controls imply that these
acute-phase reactants are markers of plaque stability. This is
supported by the fact that carotid artery stenosis is a pre-
dictor of widespread atherosclerosis23 and that atheroscle-
rosis is an inflammatory process. In atherosclerosis, macro-
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tumor necrosis factor, all of which stimulate hepatocytes to
produce fibrinogen and hsCRP. Furthermore, our findings
are in accordance with those by Levenson et al24 that
fibrinogen was elevated in subjects with silent atheroscle-
rosis, particularly in those with disease in several arterial
beds.24 Finally, within the Copenhagen City Heart Study,
patients with ischemic heart disease and thus atherosclerosis
had elevated fibrinogen.25
CONCLUSION
Our data demonstrate that elevated levels of the inflam-
matory markers fibrinogen and hsCRP are associated with
increased risk of new cerebral ischemic lesions after CEA.
Our observation also suggests the possibility that the tested
inflammatory markers may provide a method of identifying
people for whom a specific antiinflammatory therapy before
operation is necessary, a hypothesis requiring direct testing
in randomized clinical trials.
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